Amneal Pharmaceuticals (AMRX) Other Non-Current Assets (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Other Non-Current Assets of $54.9 million for Q1 2026, up 20.83% year-over-year from $45.4 million in Q1 2025, and down 5.06% quarter-over-quarter from $57.8 million in Q4 2025.
Amneal Pharmaceuticals (AMRX) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $54.9 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 20.83% year-over-year to $54.9 million; the TTM figure through Mar 2026 stood at $54.9 million (up 20.83% YoY), while the FY2025 annual figure was $57.8 million, down 3.87% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $54.9 million, down from $57.8 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $108.3 million in Q3 2022, with the low at $36.3 million in Q3 2024.
- The 5-year median for Other Non-Current Assets is $63.9 million (2022), against an average of $68.8 million.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets surged 454.39% in 2022, then tumbled 59.26% in 2024.
- Amneal Pharmaceuticals' Other Non-Current Assets stood at $103.2 million in 2022, then slumped by 46.21% to $55.5 million in 2023, then advanced by 8.31% to $60.1 million in 2024, then fell by 3.87% to $57.8 million in 2025, then dropped by 5.06% to $54.9 million in 2026.
- Business Quant data shows AMRX's Other Non-Current Assets at $54.9 million in Q1 2026, $57.8 million in Q4 2025, and $39.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 13.00 Mn |
| 10 | Amneal Pharmaceuticals | 5.72 Bn | 5.59 Bn | 334.51 Mn | 80.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.67 Mn |
| Mar 31, 2026 | 54.88 Mn |
| Dec 31, 2025 | 57.81 Mn |
| Sep 30, 2025 | 39.46 Mn |
| Jun 30, 2025 | 44.85 Mn |
| Mar 31, 2025 | 45.42 Mn |
| Dec 31, 2024 | 60.13 Mn |
| Sep 30, 2024 | 36.27 Mn |
| Jun 30, 2024 | 77.03 Mn |
| Mar 31, 2024 | 73.75 Mn |
| Dec 31, 2023 | 55.52 Mn |
| Sep 30, 2023 | 89.04 Mn |
| Jun 30, 2023 | 93.24 Mn |
| Mar 31, 2023 | 86.43 Mn |
| Dec 31, 2022 | 103.22 Mn |
| Sep 30, 2022 | 108.26 Mn |
| Jun 30, 2022 | 79.84 Mn |
| Mar 31, 2022 | 63.94 Mn |
| Dec 31, 2021 | 20.61 Mn |
| Sep 30, 2021 | 19.53 Mn |